Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | THRA | P10827 | 8/20 | 0.47 |
| ▸ | THRB | P10828 | 8/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200035 | 0.84 | NPSR1 (0.59) | NPSR1THRATHRBFFAR4POLB | |
| SCHEMBL10937131 | 0.84 | NPSR1 (0.91) | NPSR1FFAR4POLBL3MBTL1RXRA | |
| SCHEMBL23286929 | 0.81 | NPSR1 (0.48) | NPSR1THRATHRBPOLBRXRA | |
| SCHEMBL29605526 | 0.81 | NPSR1 (0.48) | NPSR1THRATHRBPOLBRXRA | |
| SCHEMBL2473673 | 0.81 | NPSR1 (0.50) | NPSR1THRATHRBL3MBTL1TSHR | |
| SCHEMBL14430309 | 0.77 | NPSR1 (0.59) | NPSR1THRATHRBFFAR4POLB | |
| SCHEMBL18830689 | 0.76 | THRA (0.56) | NPSR1THRATHRBFFAR4FFAR1 | |
| SCHEMBL12442303 | 0.76 | NPSR1 (0.63) | NPSR1THRATHRBFFAR4POLB | |
| SCHEMBL4817531 | 0.76 | NPSR1 (0.63) | NPSR1THRATHRBFFAR4POLB | |
| SCHEMBL3678217 | 0.75 | NPSR1 (0.72) | NPSR1FFAR4POLBRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2011-12-22 | — | — | US | disclosed |
| EP-2370431-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | Almirall S.A. (ES) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010072352-A1 | 1, 2, 4 -OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | ALMIRALL S.A. (ES) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311485-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AND THEIR THERAPEUTIC USE | S1PR1, S1PR2, S1PR3 | NPSR1 136/4885THRA 1322/4885THRB 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.